Agenus Q3 2026 net income drops 96% year over year to $2.8 million
AGEN•Agenus’ third-quarter 2026 net income fell 96% year over year to $2.8 million, while revenue rose to $31.5 million. Cash, cash equivalents and short-term investments totaled $86.9 million at September 30, 2026.
1. Quarterly results and milestones
Agenus reported third-quarter 2026 net income of $2.8 million, down 96% year over year, and revenue of $31.5 million. Cash, cash equivalents and short-term investments increased from the previous quarter to $86.9 million at September 30. Armenia granted the first worldwide marketing authorizations for botensilimab and balstilimab in combination, and the Phase 3 ROBBIN trial remains on track for first patient enrollment in Q1 2027. July financing proceeds are expected to support operations through Q3 2027, or through year-end 2031 if milestone-aligned warrants are fully exercised.
